Pandel® delivers a package of benefits
The mid-potency steroid that offers:
- Symptom improvement in atopic dermatitis and psoriasis1
- Pandel® demonstrated progressive symptom improvement in patients with atopic dermatitis* at all study visits1
- Pandel® demonstrated significant improvement in psoriasis symptoms by end of week 31
- The soothing feel of an emollient-based cream2
- Benefits of an emollient-rich base:
- Rehydrates the outermost layer of the skin3,4
- Restores the skin's suppleness and pliability3,4
- Benefits of an emollient-rich base:
- Once- or twice-daily application2
- Applied to affected area(s) once or twice daily, depending on severity of symptoms2
- Available in 80-g tube2
*From a 2-week, double-blind, randomized, multicenter, placebo-controlled study of 168 patients with atopic dermatitis (patients on Pandel®: n=106; patients on placebo: n=62).1
From a 3-week, double-blind, randomized, multicenter, placebo-controlled study of 168 patients with psoriasis.1
Day 21 of treatment.1
PANDEL® (hydrocortisone probutate) Cream, 0.1% is a topical prescription medication for the relief of the inflammatory (redness) and pruritic (itching) manifestations of corticosteroid-responsive skin conditions in patients 18 years of age or older.
This medication is for topical use only. Avoid contact with the eyes. The treated skin area should not be bandaged or otherwise covered or wrapped, unless directed by the physician. Therapy should be stopped when your condition gets better. If no improvement is seen within two weeks, contact the physician.
PANDEL can pass through your skin and cause adrenal gland problems. This is more likely to happen if you use PANDEL for too long, use it with other medicines that contain corticosteroids, apply it on a large area of your skin or apply it on broken skin, cover the treated area, have liver failure, or use it in pediatric patients. Your healthcare provider may do blood tests to check your adrenal gland function during and after treatment with PANDEL. Various hormonal abnormalities, increased blood sugar, and revealing underlying diabetes mellitus can also result from topical corticosteroids passing through your skin. Pediatric patients may be more susceptible to systemic toxicity.
Allergic contact dermatitis (rash) with corticosteroids is usually identified by a failure to heal rather than worsening of the condition, as seen with most topical products not containing corticosteroids. If irritation develops, discontinue PANDEL and institute appropriate therapy.
If you are pregnant or nursing a baby, consult with your physician prior to using this product.
The most frequent adverse reactions include burning, stinging, rash, red, bumpy rash, redness, itching, moderate tingling or prickling feeling, and allergic rash. Local adverse reactions that have been reported with topical corticosteroids include itching, irritation, dryness, folliculitis (swelling of the hair follicles), hypertrichosis (excessive hair growth), acneiform eruptions (acne or rashes resembling acne), hypopigmentation (loss of skin color), perioral dermatitis (rash around the mouth), allergic contact dermatitis (rash), secondary infections, skin atrophy (thinning), striae (lines on the skin), and miliaria (rash due to blocking of the sweat glands, ‘prickly heat’).
Please see the link to the Full Prescribing Information below.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
- Data on file, PharmaDerm.
- Pandel [Prescribing Information, 2017]. Melville, NY: PharmaDerm, a division of Fougera Pharmaceuticals Inc.
- Clark C. Atopic eczema management. Clin Pharmacist. 2010;2:291-298.
- Clark C. How to choose a suitable emollient. Pharm J. 2004;273:351-352.